Overview of the NINLARO study*
The treatment combination of NINLARO+
The study compared a three medication vs a two medication combination†
*The US Food and Drug Administration (FDA) approved NINLARO based on the results of this clinical study. This study tested the NINLARO treatment combination (NINLARO+
†Placebo pills are not active.
When multiple myeloma returns, taking the NINLARO treatment combination may help you live longer without your multiple myeloma getting worse
The NINLARO treatment combination (NINLARO+
Progression-free survival (PFS)
In the clinical study, people taking the NINLARO treatment combination went more than a year and a half (20.6 months) without their multiple myeloma getting worse compared to 14.7 months for people who took the lenalidomide+dexamethasone combination alone.
The NINLARO treatment combination improved the
time people lived without their disease getting worse
‡NINLARO combination=NINLARO+lenalidomide+dexamethasone; lenalidomide+dexamethasone combination=placebo+lenalidomide+dexamethasone.
In this study, people taking the NINLARO treatment combination lived a similar overall length of time after diagnosis as people who received the lenalidomide+dexamethasone combination alone.
The NINLARO treatment combination was proven to work quickly and effectively
§A 90% or greater decrease in M protein (an abnormal myeloma protein produced by myeloma cells). Also called very good partial remission.
‖‖Complete response is when there are less than 5% plasma cells in the bone marrow and blood and urine lab tests show no M protein.